GlassScriptPhysician profile
Sarah E Neumann
NPI 1487781092
$8,009.98
in general payments reported to CMS, 2019-2025
28 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,900 · 2022: $2,364 · 2023: $1,081 · 2024: $518 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.84 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,279.63 | 2021-2025 | |
| Janssen Biotech, INC. | $742.95 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Scientific Affairs, LLC | $434.88 | 2022-2023 | Tremfya |
| Leo Pharma INC. | $377.23 | 2021-2023 | Adbry |
| Genzyme Corporation | $336.10 | 2021-2023 | |
| Pfizer INC. | $248.60 | 2021-2025 | |
| Lilly USA, LLC | $226.16 | 2021-2023 | Taltz |
| Amgen INC. | $216.47 | 2022-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $202.72 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $170.55 | 2021-2022 | |
| Galderma Laboratories, L.P. | $116.22 | 2021-2024 | |
| Incyte Corporation | $114.28 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $71.46 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $58.37 | 2021-2025 | |
| Biofrontera INC. | $55.22 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $49.17 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.86 | 2022-2023 | Jublia |
| Ucb, INC. | $36.80 | 2021-2024 | Bimzelx |
| Epi Health, LLC | $35.02 | 2021-2022 | |
| Dermavant Sciences, INC. | $34.34 | 2023 | Vtama |
| Botanix Sb INC | $27.02 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $26.68 | 2023 | |
| Mayne Pharma Commercial LLC | $21.82 | 2022 | |
| Dermira, INC. | $18.59 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.56 | 2022 | |
| Allergan, INC. | $17.61 | 2022 | |
| Merz North America, INC. | $17.22 | 2021 | |
| Organon LLC | $11.45 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.